ONC
BeiGene, Ltd.
NASDAQ: ONC · HEALTHCARE · BIOTECHNOLOGY
$295.27
+1.54% today
Updated 2026-04-30
Market cap
$33.18B
P/E ratio
120.52
P/S ratio
6.21x
EPS (TTM)
$2.48
Dividend yield
—
52W range
$218 – $385
Volume
0.2M
WallStSmart proprietary scores
42
out of 100
Grade: D
Sell
Investment rating
8.0
Growth
A6.5
Quality
B5.0
Profitability
C+5.7
Valuation
C+5/9
Piotroski F-Score
Moderate
0.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$408.20
+38.25%
12-Month target
$16.73
-94.33%
Intrinsic (DCF)
$1,738.29
Margin of safety
+79.79%
7 Strong Buy18 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $131.28M — positive
+ Revenue growth 32.80% QoQ
+ 79.79% below intrinsic value
+ Debt/equity 0.25x — low leverage
Risks
- Altman Z 0.26 — distress zone
- P/E 120.52x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $1.42B | $2.46B | $3.81B | $5.34B | $5.34B | $6.1B |
| Net income | $-2.00B | $-881.71M | $-644.79M | $286.93M | $66.50M | — |
| EPS | — | — | — | — | $2.48 | $3.80 |
| Free cash flow | $-1.97B | $-1.75B | $-669.77M | $941.74M | $131.28M | — |
| Profit margin | -141.52% | -35.86% | -16.92% | 5.37% | 5.37% | — |
Peer comparison
Smart narrative
BeiGene, Ltd. trades at $295.27. representing a P/E of 120.52x trailing earnings. Our Smart Value Score of 42/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 0.26, it sits in the distress. TTM revenue stands at $5.34B. with profit margins at 5.37%. Our DCF model estimates intrinsic value at $1,738.29.
Frequently asked questions
What is BeiGene, Ltd.'s stock price?
BeiGene, Ltd. (ONC) trades at $295.27.
Is BeiGene, Ltd. overvalued?
Smart Value Score 42/100 (Grade D, Sell). DCF value $1,738.29.
What is the price target of BeiGene, Ltd. (ONC)?
The analyst target price is $408.20, representing +38.2% upside from the current price of $295.27.
What is the intrinsic value of BeiGene, Ltd. (ONC)?
Based on our DCF model, intrinsic value is $1,738.29, a +79.8% margin of safety versus $295.27.
What is the future stock price of ONC by 2030?
Our research-backed model estimates BeiGene, Ltd. could reach $1,391.45 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is BeiGene, Ltd.'s revenue?
TTM revenue is $5.34B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
0.26 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.21x
ROE7.46%
Beta0.54
50D MA$309.27
200D MA$319.91
Shares out0.10B
Float1.01B
Short ratio—
Avg volume0.2M
Performance
1 week-3.32%
1 month-5.72%
3 months-14.57%
YTD-4.28%
1 year—
3 years—
5 years—